New drug trial halted early for advanced cancers
NCT ID NCT06287463
Summary
This early-stage trial tested an experimental drug called DCC-3084, both alone and combined with other cancer therapies, in people with advanced solid tumors driven by specific genetic mutations. The study aimed to find a safe dose and see if the drug could shrink tumors. It was open to adults who had run out of standard treatment options, but the trial was terminated early and did not complete its planned phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology Virginia
Fairfax, Virginia, 22031, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
SCRI Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
SCRI HealthONE
Denver, Colorado, 80218, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
University of Southern California - Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.